265 related articles for article (PubMed ID: 26123415)
1. Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.
Wang XC; Zhu DM; Shan YX
Am J Cardiovasc Drugs; 2015 Dec; 15(6):429-37. PubMed ID: 26123415
[TBL] [Abstract][Full Text] [Related]
2. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
[TBL] [Abstract][Full Text] [Related]
3. Nesiritide Therapy Is Associated With Better Clinical Outcomes Than Dobutamine Therapy in Heart Failure.
Kong LG; Wang CL; Zhao D; Wang B
Am J Ther; 2017; 24(2):e181-e188. PubMed ID: 26164026
[TBL] [Abstract][Full Text] [Related]
4. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Abraham WT; Adams KF; Fonarow GC; Costanzo MR; Berkowitz RL; LeJemtel TH; Cheng ML; Wynne J; ;
J Am Coll Cardiol; 2005 Jul; 46(1):57-64. PubMed ID: 15992636
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure.
Gerhard T; Zineh I; Winterstein AG; Hartzema AG
Pharmacotherapy; 2006 Jan; 26(1):34-43. PubMed ID: 16509026
[TBL] [Abstract][Full Text] [Related]
6. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure.
Silver MA; Horton DP; Ghali JK; Elkayam U
J Am Coll Cardiol; 2002 Mar; 39(5):798-803. PubMed ID: 11869844
[TBL] [Abstract][Full Text] [Related]
7. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure.
Aronson D; Burger AJ
Am Heart J; 2004 Nov; 148(5):e16. PubMed ID: 15523294
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan and nesiritide as a combination therapy in patients with acute heart failure.
Jia Z; Guo M; Zhang LY; Zhang YQ; Liang HQ; Song Y
Am J Med Sci; 2015 May; 349(5):398-405. PubMed ID: 25853935
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of recombinant human brain natriuretic peptide and dobutamine on acute decompensated heart failure patients with different blood BNP levels.
Pan HY; Zhu JH; Gu Y; Yu XH; Pan M; Niu HY
BMC Cardiovasc Disord; 2014 Mar; 14():31. PubMed ID: 24593826
[TBL] [Abstract][Full Text] [Related]
10. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study.
Burger AJ; Horton DP; LeJemtel T; Ghali JK; Torre G; Dennish G; Koren M; Dinerman J; Silver M; Cheng ML; Elkayam U;
Am Heart J; 2002 Dec; 144(6):1102-8. PubMed ID: 12486437
[TBL] [Abstract][Full Text] [Related]
11. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
12. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
Kurien S; Warfield KT; Wood CM; Miller WL
Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
[TBL] [Abstract][Full Text] [Related]
13. Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure.
King JB; Shah RU; Sainski-Nguyen A; Biskupiak J; Munger MA; Bress AP
Pharmacotherapy; 2017 Jun; 37(6):662-672. PubMed ID: 28475215
[TBL] [Abstract][Full Text] [Related]
14. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.
Sackner-Bernstein JD; Kowalski M; Fox M; Aaronson K
JAMA; 2005 Apr; 293(15):1900-5. PubMed ID: 15840865
[TBL] [Abstract][Full Text] [Related]
15. Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide.
Noviasky JA
Pharmacotherapy; 2007 May; 27(5):626-32. PubMed ID: 17461696
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy.
Burger AJ; Elkayam U; Neibaur MT; Haught H; Ghali J; Horton DP; Aronson D
Am J Cardiol; 2001 Jul; 88(1):35-9. PubMed ID: 11423055
[TBL] [Abstract][Full Text] [Related]
17. Risk of death with nesiritide.
Burger AJ
JAMA; 2005 Aug; 294(8):897; author reply 898. PubMed ID: 16118377
[No Abstract] [Full Text] [Related]
18. Nesiritide in acute decompensated heart failure: a pooled analysis of randomized controlled trials.
Abraham WT; Trupp RJ; Jarjoura D
Clin Cardiol; 2010 Aug; 33(8):484-9. PubMed ID: 20734445
[TBL] [Abstract][Full Text] [Related]
19. The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure.
Strain WD
Int J Clin Pract; 2004 Nov; 58(11):1081-7. PubMed ID: 15605677
[TBL] [Abstract][Full Text] [Related]
20. The role of nesiritide in heart failure.
Tong AT; Rozner MA
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):823-34. PubMed ID: 19538002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
